Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, Fiorella S, Forti G, Franceschi M, Gallina S, Giorgetti G, Grasso G, Larussa T, Luzza F, Penna A, Pica R, Piergallini S, Porciello S, Pranzo G, Rodino' S, Scorza S, Sebkova L, Zampaletta C, Elisei W, Picchio M.
Tursi A, et al. Among authors: ferronato a.
Eur J Gastroenterol Hepatol. 2021 May 1;33(5):670-679. doi: 10.1097/MEG.0000000000002087.
Eur J Gastroenterol Hepatol. 2021.
PMID: 33741797